• Skip to main navigation
  • Skip to search bar
  • Skip to main content
  • Skip to footer
  • Log in

  • GIN Website
  • Guide to the Library
Press enter or spacebar to select a desired language.
  • Log in
Guidelines International Network (GIN)
Powered by EBSCO
  • GIN Website
  • Guide to the Library
    Search International Guidelines Library

    The library contains links to guidelines published or endorsed by GIN member organisations from across the globe. It also contains a registry of planned guidelines and guidelines in development. Non members are actively encouraged to register their guidelines in development. Contact [email protected] to find out how. To learn more about GIN and membership, click the website button above.

    Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

    • View Publication
    • Download Tools & Resources
    • PROSPERO
      • My Saved Lists
    Collection
    Guidelines International Network
    MeSH Terms

    Adenocarcinoma of Lung (C04.557.470.200.025.022); Carcinoma, Non-Small-Cell Lung (C04.588.894.797.520.109.220.249); Lung neoplasms (C04.588.894.797.520); Carcinoma, Bronchogenic (C04.588.894.797.520.109.220); "Genes, erbB-1" (G05.360.340.024.340.375.500.791.295.300); "ErbB Receptors" (D08.811.913.696.620.682.725.400.009); "Proto-Oncogene proteins p21(ras)" (D08.811.277.040.330.300.400.500.600); "Anaplastic lymphoma kinase” (D08.811.913.696.620.682.725.400.002); "Proto-oncogene proteins" (D12.776.624.664.700); "Proto-oncogene proteins B-raf" (D08.811.913.696.620.682.700.559.842.374); "Receptor, trkA" (D08.811.913.696.620.682.725.400.660); "Receptor, trkB" (D08.811.913.696.620.682.725.400.700); "Receptor, trkC" (D08.811.913.696.620.682.725.400.800); "Proto-oncogene proteins c-met" (D08.811.913.696.620.682.725.400.075); "Proto-oncogene proteins c-ret" (D08.811.913.696.620.682.725.400.087); Receptor, ErbB-2 (D08.811.913.696.620.682.725.400.009.400); Proto-oncogene proteins c-akt (D08.811.913.696.620.682.700.755); Discoidin Domain Receptor 2 (D08.811.913.696.620.682.725.400.005.750); Receptor, Fibroblast growth factor, type 1 (D08.811.913.696.620.682.725.400.177); Receptor, Fibroblast growth factor, type 2 (D08.811.913.696.620.682.725.400.178); Receptor, Fibroblast growth factor, type 3 (D08.811.913.696.620.682.725.400.179); Receptor, Fibroblast growth factor, type 4 (D08.811.913.696.620.682.725.400.180); "Kelch-like ECH-associated protein 1" (D12.644.360.024.306); "MAP Kinase Kinase 1" (D08.811.913.696.620.682.700.565.100); Neuregulin-1 (D12.644.276.860.550.750); Class I Phosphatidylinositol 3-Kinases (D08.811.913.696.620.500.100.100); Tumor suppressor protein p53 (D12.776.157.687.650)

    Keywords
    tki, molecular testing, treatment, lung cancer patients, targeted tyrosine kinase inhibitors, cap, college of american pathologists, international association for the study of lung cancer, association for molecular pathology, guideline update, evidence-based guideline, clinical molecular testing of non-small cell lung cancers, nsclc
    Record Publish Year
    2018
    Publication Date
    Original Published: June 2013
    Update Published: January 22, 2018
    Expected Publication Date
    Update: Q3, 2025
    Guideline Contact
    Christina Ventura ([email protected])
    Publication Scope
    assessment
    Countries of Application
    United States
    Guideline Publication Status
    Under Review
    Languages
    English
    Authors
    CAP (US)
    Publication Year
    2018

    Stacks

    The new library experience

    Copyright Footer
    Powered By EBSCO Stacks 4.0.121.4 Staff Login